GlassScriptPhysician profile
Katrina Evette Allen
NPI 1336123744
$5,632.22
in general payments reported to CMS, 2019-2025
37 companies · $503 in 2025
The $503 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $220 · 2021: $281 · 2022: $645 · 2023: $710 · 2024: $2,728 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,816 · Consulting Fee: $1,800 · Education: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,815.90 |
| Consulting Fee | $1,800.00 |
| Education | $325.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $1,841.04 | 2024-2025 | |
| Abbvie INC. | $676.38 | 2019-2023 | Lo Loestrin Fe, Orilissa, Liletta |
| Pfizer INC. | $429.42 | 2019-2025 | |
| Astellas Pharma US INC | $327.40 | 2022-2025 | Veozah |
| Medical Device Business Services, INC. | $325.00 | 2024 | |
| Exeltis, USA INC. | $246.95 | 2019-2025 | Slynd |
| Mayne Pharma Commercial LLC | $198.88 | 2021-2023 | |
| Hologic Sales and Service, LLC | $171.59 | 2019-2024 | Myosure Tissue Removal Device |
| Sumitomo Pharma America, INC. | $160.34 | 2023-2025 | Myfembree |
| Organon LLC | $137.17 | 2022-2025 | Nexplanon, Jada System |
| Millicent US INC | $110.48 | 2023-2025 | Intrarosa, Femlyv |
| Shield Therapeutics INC | $94.73 | 2024 | |
| Allergan, INC. | $79.54 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $75.20 | 2019-2024 | Gardasil 9, Gardasil |
| Axonics, INC. | $63.64 | 2023-2024 | Bulkamid |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $56.97 | 2019-2020 | |
| Biogen, INC. | $52.47 | 2024-2025 | Zurzuvae, Vumerity |
| Evofem Biosciences, INC. | $43.39 | 2021-2022 | |
| Myovant Sciences INC. | $40.98 | 2022 | |
| Medtronic, INC. | $40.43 | 2024 | Ligasure |
| Avion Pharmaceuticals | $40.14 | 2019-2023 | Balcoltra |
| Baxter Healthcare | $38.74 | 2025 | Perclot |
| Aspira Women'S Health INC | $36.62 | 2022 | |
| Agile Therapeutics, INC. | $35.14 | 2022-2023 | Twirla |
| Therapeuticsmd, INC. | $33.84 | 2019-2021 | |
| Innovation Technologies INC | $32.84 | 2023 | Irrisept |
| Duchesnay USA Incorporated | $31.84 | 2019-2020 | |
| Minerva Surgical, INC | $31.38 | 2024-2025 | |
| Organogenesis INC. | $30.40 | 2025 | Cygnus Matrix |
| Davol INC. | $30.37 | 2025 | Arista |
| Daiichi Sankyo INC. | $25.19 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.67 | 2024 | |
| Conmed Corporation | $17.37 | 2025 | Conmed Specimen Retrieval, Airseal |
| Bausch Health US, LLC | $16.20 | 2022 | |
| Meditrina | $13.18 | 2024 | |
| Ethicon US, LLC | $12.90 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katrina Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.